Abingdon Health PLC (AIM:ABDX), the York-based developer and manufacturer of rapid diagnostic tests, will begin trading on the OTCQB Venture Market in the United States under the ticker ABDXF from 21 April 2026.
The move follows the company's September 2025 announcement of a second phase of expansion at its Madison, Wisconsin facility, funded by a capital raise completed in October 2025.
The US site is being built out to mirror Abingdon Health's UK operations, giving customers the option to manufacture under identical conditions and quality management systems on either side of the Atlantic.
The company said the geographic flexibility would be particularly valuable to US customers during a period of tariff and supply chain uncertainty, with products able to carry both "developed in the USA" and "made in the USA" credentials.
Abingdon Health will face no additional SEC reporting obligations as a result of the listing, keeping ongoing costs minimal.
The company's AIM listing under the ticker ABDX will remain in place.